EGFR-directed monoclonal antibodies in non-small cell lung cancer (Q38072670)

28 August 2017

1 reference

title

EGFR-directed monoclonal antibodies in non-small cell lung cancer (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

Robert Pirker

1

1 reference

28 August 2017

publication date

9 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

47-53

1 reference

Targeted therapies in lung cancer.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Chemoprevention of breast cancer: a model for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Monoclonal antibodies against EGFR in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0244-7

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23300028

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23300028

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23300028

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-012-0244-7

1 reference

Dimensions Publication ID

28 August 2017

1009734403

0 references

1 reference